• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHAO Yuekui, TANG Shanshan, ZHANG Yanfeng, ZONG Li, JIN Liang. Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(2): 134-139. DOI: 10.11665/j.issn.1000-5048.20160202
Citation: ZHAO Yuekui, TANG Shanshan, ZHANG Yanfeng, ZONG Li, JIN Liang. Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(2): 134-139. DOI: 10.11665/j.issn.1000-5048.20160202
shu

Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy

More Information
    Graphical Abstract
    • Abstract
  • Mesenchymal stem cells(MSCs)were derived from the early development stage of mesoderm and ectoderm and considered as one of the important members of stem cells family. Besides that, MSCs can be isolated easily and don′t have a limitation of moral and ethical problems. Moreover, MSCs can be expanded in vitro which make it possible to use in industrial preparation. Moreover, MSCs possess low immunogenicity and has the ability to home to damaged tissues, tumors, and metastases. Therefore, MSCs possess a set of fairly unique properties which make them ideally suited for clinical applications. This review summarizes the main properties of MSCs and its new progress in drug delivery system in the field of cancer therapy as a basis of further utility of engineered MSCs in the design of targeting drug delivery system.
    • FullText(HTML)
    • References (50)
  • [1]
    Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
    [2]
    Chen W,ZhengR,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
    [3]
    Zhao Y,Ren W,Zhong T,et al.Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity[J].J Control Release,2016,222:56-66.
    [4]
    Beduneau A, Ma Z, Grotepas CB, et al. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles[J].PLoS One,2009,4(2):1-12.
    [5]
    Son GM, Kim HY, Ryu JH, et al. Self-assembled polymeric micelles based on hyaluronic acid-g-poly(D,L-lactide-co-glycolide)copolymer for tumor targeting[J].Int J Mol Sci,2014,15(9):16057-16068.
    [6]
    Huang WC,Chiang WH,Cheng YH,et al.Tumortropic monocyte-mediated delivery of echogenic polymer bubbles and therapeutic vesicles for chemotherapy of tumor hypoxia[J].Biomaterials,2015,71:71-83.
    [7]
    Hu YL,Fu YH,Tabata Y,et al.Mesenchymal stem cells:a promising targeted-delivery vehicle in cancer gene therapy[J].J Control Release,2010,147(2):154-162.
    [8]
    Elena V,Howard E.Cell-mediated drugs delivery[J].Expert Opin Drug Deliv,2011,8(4):415-433.
    [9]
    Anselmo AC,Gupta V,Zern BJ,et al.Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells[J].ACS Nano,2013,7(12):11129-11137.
    [10]
    Muthana M,Giannoudis A,Scott SD,et al.Use of macrophages to target therapeutic adenovirus to human prostate tumors[J].Cancer Res,2011,71(5):1805-1815.
    [11]
    Friedenstein AJ,Piatetzky-Shapiro II,Petrakova KV.Osteogenesis in transplants of bone marrow cells[J].J Embryol Exp Morphol,1966,16(3):381-390.
    [12]
    Dominici M,Le BK,Mueller I,et al.Minimal criteria for defining multipotentmesenchymal stromal cells.The international society for cellular therapy position statement[J].Cytotherapy,2006,8(4):315-317.
    [13]
    Zhao S,Wehner R.Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders[J].Stem Cells Dev,2010,19(5):607-614.
    [14]
    Egea V,Baumgarten L,Schichor C,et al.TNF-alpha respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma[J].Cell Death Differ,2011,18(5):853-863.
    [15]
    Shinojima N,Hossain A,Takezaki T,et al.TGF-beta mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells[J].Cancer Res,2013,73(7):2333-2344.
    [16]
    Dwyer RM,Potter-Beirne SM,Harrington KA,et al.Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells[J].Clin Cancer Res,2007,13(17):5020-5027.
    [17]
    Gao P,Ding Q,Wu Z,et al.Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma[J].Cancer Lett,2010,290(2):157-166.
    [18]
    Kucerova L, Altanerova V, Matuskova M, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy[J].Cancer Res,2007,67(13):6304-6313.
    [19]
    Zhu Y,Cheng M,Yang Z,et al.Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts[J].Drug Des Devel Ther,2014,8:2449-2462.
    [20]
    Park JS,Suryaprakash S,Lao YH,et al.Engineering mesenchymal stem cells for regenerative medicine and drug delivery[J].Methods,2015,84:3-16.
    [21]
    Nakamura K,Ito Y,Kawano Y,et al.Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model[J].Gene Ther,2004,11(14):1155-1164.
    [22]
    Seo SH,Kim KS,Park SH,et al.The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity[J].Gene Ther,2011,18(5):488-495.
    [23]
    Darinka GA,Tatjana K,Lia R,et al.Perspectives in engineered mesenchymal stem/stromal cells based anticancer drug delivery systems[J].Recent Pat Anticancer Drug Discov,2016,11(1):1-13.
    [24]
    Ling X,Marini F,Konopleva M.Mesenchymal stem cells overexpressing IFN-beta inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model[J].Cancer Microenviron,2010,3(1):83-95.
    [25]
    Loebinger MR,Eddaoudi A,Davies D,et al.Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer[J].Cancer Res,2009,69(10):4134-4142.
    [26]
    Xin H,Kanehira M,Mizuguchi H,et al.Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells[J].Stem Cells,2007,25(7):1618-1626.
    [27]
    Zheng L,Zhang D,Chen X,et al.Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer[J].PLoS One,2012,7(7):1-10.
    [28]
    Park JH,Ryu CH,Kim MJ,et al.Combination therapy for gliomas using temozolomide and interferon-beta secreting human bone marrow derived mesenchymal stem cells[J].J Korean Neurosurg Soc,2015,57(5):323-328.
    [29]
    Yan C,Li S,Li Z,et al.Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery:a double-target therapy against non-Hodgkin′s lymphoma[J].Mol Pharm,2013,10(1):142-151.
    [30]
    Song C,Xiang J,Tang J,et al.Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy[J].Hum Gene Ther,2011,22(4):439-449.
    [31]
    Amara I,Touati W,Beaune P,et al.Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors[J].Biochimie,2014,105:4-11.
    [32]
    Hu YL,Huang B,Zhang TY,et al.Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection[J].Mol Pharm,2012,9(9):2698-2709.
    [33]
    Hu YL,Miao PH,Huang B,et al.Reversal of tumor growth by gene modification of mesenchymal stem cells using spermine-pullulan/DNA nanoparticles[J].J Biomed Nanotechnol,2014,10(2):299-308
    [34]
    Zhang TY, Huang B, Wu HB, et al. Synergistic effects of co-administration of suicide gene expressing mesenchymal stem cells and prodrug-encapsulated liposome on aggressive lung melanoma metastases in mice[J].J Control Release,2015,209:260-271.
    [35]
    Gheisari YSM,Azadmanesh K,Zeinali S,et al.Multipotentmesenchymal stromal cells:optimization and comparison of five cationic polymer-based gene delivery methods[J].Cytotherapy,2008,10(8),815-823.
    [36]
    Yin PT,Shah S,Pasquale NJ,et al.Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer[J].Biomaterials,2016,81:46-57.
    [37]
    García-Castro J,Alemany R,Cascalló M,et al.Treatment of metastatic neuroblastoma with systemic oncolyticvirotherapy delivered by autologous mesenchymal stem cells:an exploratory study[J].Cancer Gene Ther,2010,17(7):476-483.
    [38]
    Sadhukha T,O′Brien TD,Prabha S,et al.Nano-engineered mesenchymal stem cells as targeted therapeutic carriers[J].J Control Release,2014,196:243-251.
    [39]
    Tripodo G,Chlapanidas T,Perteghella S,et al.Mesenchymal stromal cells loading curcumin-INVITE-micelles:a drug delivery system for neurodegenerative diseases[J].Colloids Surf B Biointerfaces,2015,125:300-308.
    [40]
    Roger M,Clavreul A,Venier-Julienne MC,et al.Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors[J].Biomaterials,2010,31(32):8393-8401.
    [41]
    Li L, Guan YQ, Liu HY, et al. Silica nanorattle doxorubicin anchored mesenchymal stem cells for tumor-tropic therapy[J].ACS Nano,2011,5(9):7462-7470.
    [42]
    Zhang X,Yao S,Liu C,et al.Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy[J].Biomaterials,2015,39:269-281.
    [43]
    Saari H,Lazaro-Ibanez E,Viitala T,et al.Microvesicle-and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells[J].J Control Release,2015,220:727-737.
    [44]
    Lai RC,Yeo RW,Tan KH,et al.Exosomes for drug delivery—a novel application for the mesenchymal stem cell[J].Biotechnol Adv,2013,31(5):543-551.
    [45]
    Katakowski M,Buller B,Zheng X,et al.Exosomes from marrow stromal cells expressing miR-146b inhibitglioma growth[J].Cancer Lett,2013,335(1):201-204.
    [46]
    Pascucci L,Cocce V,Bonomi A,et al.Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth:a new approach for drug delivery[J].J Control Release,2014,192:262-270.
    [47]
    Salem HK,Thiemermann C.Mesenchymal stromal cells:current understanding and clinical status[J].Stem Cells,2010,28(3):585-596.
    [48]
    Zhao Q,Ren H,Han Z,et al.Mesenchymal stem cells:immunomodulatory capability and clinical potential in immune diseases[J].J Cell Immunother,2015,78(3):343-346.
    [49]
    Huang B,Tabata Y,Gao JQ,et al.Mesenchymal stem cells as therapeutic agents and potential targeted gene delivery vehicle for brain diseases[J].J Control Release,2012,162(2):464-473.
    [50]
    Bagó JR,Pegna GJ,Okolie O,et al.Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer[J].Biomaterials,2016,84:42-53.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (1371) PDF downloads (2371) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：297264

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return